Live symbol workspace

AZN market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $171.61

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$163.03

Resistance

$180.19

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$171.61

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

35%

No prior-week baseline yet

Avg confidence across 3 calls in the last 7 days

What sources say

No news-sourced AI calls in the last 30 days.

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

AZN News Intelligence (1 articles)

AI-curated news influencing AZN price, sentiment, and trend

Explore All AZN News with AI Analysis

Stocks

3 hours, 12 minutes ago

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it …

Impact on AZN: The trial flop may lead to a decline in AstraZeneca's stock price, …

AstraZeneca's trial flop raises concerns about its pipeline premium, potentially impacting its valuation and the … High (80%)

View full analysis →

CNBC 80% confidence